SEC Form 3 · accession 0001192482-16-000497
Aevi Genomic Medicine, Inc. · GNMX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Brian Piper
Officer — Chief Financial Officer
Period of report
Feb 9, 2016
Accepted (ET)
Feb 18, 2016 · 8:56 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001138776
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | holding | — | — | — | 2,439 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $6.45 | holding | — | — | — | Apr 16, 2014 | Apr 16, 2024 | Common Stock | 250,000 | — | D |
| Stock Option (right to buy)F2 | $7.01 | holding | — | — | — | Feb 18, 2015 | Feb 18, 2025 | Common Stock | 50,000 | — | D |
Explanation of responses
- F1The option award vests in three equal installments on April 16, 2015, 2016 and 2017.
- F2The option award vests in four equal installments on February 18, 2016, 2017, 2018 and 2019.